Structure-function - Based quantitative brain image analysis

PET Clinics

Volumn 5, Issue 2, 2010, Pages 155-168

  Zaidi, Habib ^a,b   Montandon, Marie Louise ^a   Assal, Frédéric ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Image fusion; Molecular brain imaging; MRI; Neurodegenerative disease; PET; PET MRI; Quantification; Structural brain imaging

Indexed keywords

ARTICLE; BRAIN FUNCTION; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; NEUROIMAGING; PERFUSION WEIGHTED IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 79953192705     PISSN: 15568598     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpet.2010.02.003     Document Type: Article

References (119)

1. Gilman S. Imaging the brain. First of two parts. N Engl J Med 1998;338:812-20.
2. Hammoud DA, Hoffman JM, Pomper MG. Molecular neuroimaging: from conventional to emerging techniques. Radiology 2007;245:21-42. (Pubitemid 47417787)
3. Hu X, Norris DG. Advances in high-field magnetic resonance imaging. Annu Rev Biomed Eng 2004; 6:157-84. (Pubitemid 39209496)
4. Cudalbu C, Mlynarik V, Xin L, et al. Comparison of T1 relaxation times of the neurochemical profile in rat brain at 9.4 tesla and 14.1 tesla. Magn Reson Med 2009;62:862-7.
5. van der Zwaag W, Francis S, Head K, et al. fMRI at 1.5, 3 and 7 T: characterising BOLD signal changes. Neuroimage 2009;47:1425-34.
6. Atkinson IC, Renteria L, Burd H, et al. Safety of human MRI at static fields above the FDA 8 T guideline: sodium imaging at 9.4 T does not affect vital signs or cognitive ability. J Magn Reson Imaging 2007;26:1222-7. (Pubitemid 350058290)
7. Jacobs AH, Li H, Winkeler A, et al. PET-based molecular imaging in neuroscience. Eur J Nucl Med Mol Imaging 2003;30:1051-65. (Pubitemid 37086952)
8. Zaidi H, Montandon M-L. The new challenges of brain PET imaging technology. Curr Med Imaging Rev 2006;2:3-13. (Pubitemid 44027793)
9. Sossi V. Cutting-edge brain imaging with positron emission tomography. PET Clin 2007;2:91-104.
10. Schlemmer HP, Pichler BJ, Schmand M, et al. Simultaneous MR/PET imaging of the human brain: feasibility study. Radiology 2008;248:1028-35.
11. Cho ZH, Son YD, Kim HK, et al. A fusion PETMRI system with a high-resolution research tomograph-PET and ultra-high field 7.0 T-MRI for the molecular-genetic imaging of the brain. Proteomics 2008;8:1302-23.
12. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56: 1143-53.
13. Devanand DP, Habeck CG, Tabert MH, et al. PET network abnormalities and cognitive decline in patients with mild cognitive impairment. Neuropsychopharmacology 2006;31:1327-34. (Pubitemid 43971849)
14. Jack CR Jr, Petersen RC, Xu YC, et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology 1997; 49:786-94. (Pubitemid 27428023)
15. Sencakova D, Graff-Radford NR, Willis FB, et al. Hippocampal atrophy correlates with clinical features of Alzheimer disease in African Americans. Arch Neurol 2001;58:1593-7. (Pubitemid 32963223)
16. Vermersch P, Leys D, Scheltens P, et al. Visual rating of hippocampal atrophy: correlation with volumetry. J Neurol Neurosurg Psychiatry 1994; 57:1015. (Pubitemid 24251084)
17. Wahlund LO, Julin P, Johansson SE, et al. Visual rating and volumetry of the medial temporal lobe on magnetic resonance imaging in dementia: a comparative study. J Neurol Neurosurg Psychiatry 2000;69:630-5.
18. Bresciani L, Rossi R, Testa C, et al. Visual assessment of medial temporal atrophy on MR films in Alzheimer's disease: comparison with volumetry. Aging Clin Exp Res 2005;17:8-13. (Pubitemid 43073053)
19. Burton EJ, Barber R, Mukaetova-Ladinska EB, et al. Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis. Brain 2009;132:195-203.
20. Wahlund LO, Almkvist O, Blennow K, et al. Evidence-based evaluation of magnetic resonance imaging as a diagnostic tool in dementia workup. Top Magn Reson Imaging 2005;16:427-37. (Pubitemid 44699400)
21. Baron JC, Chetelat G, Desgranges B, et al. In vivo mapping of gray matter loss with voxel-based morphometry in mild Alzheimer's disease. Neuroimage 2001;14:298-309. (Pubitemid 32709545)
22. Frisoni GB, Testa C, Zorzan A, et al. Detection of grey matter loss in mild Alzheimer's disease with voxel based morphometry. J Neurol Neurosurg Psychiatry 2002;73:657-64. (Pubitemid 35448849)
23. Boxer AL, Rankin KP, Miller BL, et al. Cinguloparietal atrophy distinguishes Alzheimer disease from semantic dementia. Arch Neurol 2003;60:949-56. (Pubitemid 36858354)
24. Ishii K, Kawachi T, Sasaki H, et al. Voxel-based morphometric comparison between early- and late-onset mild Alzheimer's disease and assessment of diagnostic performance of z score images. AJNR Am J Neuroradiol 2005;26:333-40. (Pubitemid 43073309)
25. Whitwell JL, Shiung MM, Przybelski SA, et al. MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment. Neurology 2008;70:512-20. (Pubitemid 351653375)
26. Short RA, Broderick DF, Patton A, et al. Different patterns of magnetic resonance imaging atrophy for frontotemporal lobar degeneration syndromes. Arch Neurol 2005;62:1106-10. (Pubitemid 41043731)
27. Mummery CJ, Patterson K, Price CJ, et al. A voxelbased morphometry study of semantic dementia: relationship between temporal lobe atrophy and semantic memory. Ann Neurol 2000; 47:36-45. (Pubitemid 30033648)
28. Rosen HJ, Gorno-Tempini ML, Goldman WP, et al. Patterns of brain atrophy in frontotemporal dementia and semantic dementia. Neurology 2002;58:198-208. (Pubitemid 34084208)
29. CE Krueger, DL Dean, HJ Rosen, et al. Longitudinal rates of lobar atrophy in frontotemporal dementia, semantic dementia, and Alzheimer's disease. Alzheimer Dis Assoc Disord 2010;24:43-8.
30. Pereira JM, Williams GB, Acosta-Cabronero J, et al. Atrophy patterns in histologic vs clinical groupings of frontotemporal lobar degeneration. Neurology 2009;72:1653-60.
31. Middelkoop HA, van der Flier WM, Burton EJ, et al. Dementia with Lewy bodies and AD are not associated with occipital lobe atrophy on MRI. Neurology 2001;57:2117-20. (Pubitemid 33126885)
32. Tam CW, Burton EJ, McKeith IG, et al. Temporal lobe atrophy on MRI in Parkinson disease with dementia: a comparison with Alzheimer disease and dementia with Lewy bodies. Neurology 2005; 64:861-5. (Pubitemid 40316326)
33. Whitwell JL, Weigand SD, Shiung MM, et al. Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. Brain 2007;130:708-19. (Pubitemid 46410745)
34. Kenny ER, Burton EJ, O'Brien JT. A volumetric magnetic resonance imaging study of entorhinal cortex volume in dementia with lewy bodies. A comparison with Alzheimer's disease and Parkinson's disease with and without dementia. Dement Geriatr Cogn Disord 2008;26:218-25.
35. Boxer AL, Geschwind MD, Belfor N, et al. Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. Arch Neurol 2006;63:81-6. (Pubitemid 43063865)
36. Josephs KA, Whitwell JL, Dickson DW, et al. Voxelbased morphometry in autopsy proven PSP and CBD. Neurobiol Aging 2008;29:280-9.
37. Koyama M, Yagishita A, Nakata Y, et al. Imaging of corticobasal degeneration syndrome. Neuroradiology 2007;49:905-12. (Pubitemid 350104840)
38. Varrone A, Asenbaum S, Vander Borght T, et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging 2009;36:2103-10.
39. Waxman AD, Herholz K, Lewis DH, et al. Society of Nuclear Medicine Procedure Guideline for FDG PET brain imaging. Available at: http://interactive. snm.org/index.cfm?PageID5772. Accessed January 30, 2010.
40. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-19. (Pubitemid 38269583)
41. Cohen RM. The application of positron-emitting molecular imaging tracers in Alzheimer's disease. Mol Imaging Biol 2007;9:204-16. (Pubitemid 47028736)
42. Mosconi L, Nacmias B, Sorbi S, et al. Brain metabolic decreases related to the dose of the ApoE e4 allele in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004;75:370-6. (Pubitemid 38338764)
43. Nihashi T, Yatsuya H, Hayasaka K, et al. Direct comparison study between FDG-PET and IMPSPECT for diagnosing Alzheimer's disease using 3D-SSP analysis in the same patients. Radiat Med 2007;25:255-62. (Pubitemid 351928035)
44. Del Sole A, Clerici F, Chiti A, et al. Individual cerebral metabolic deficits in Alzheimer's disease and amnestic mild cognitive impairment: an FDG PETstudy. Eur J Nucl Med Mol Imaging 2008;35:1357-66.
45. Minoshima S, Giordani B, Berent S, et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997;42: 85-94. (Pubitemid 27304784)
46. Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 2001;286:2120-7. (Pubitemid 34041597)
47. Foster NL, Heidebrink JL, Clark CM, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain 2007; 130:2616-35. (Pubitemid 47511706)
48. Ishii K, Imamura T, Sasaki M, et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease. Neurology 1998; 51:125-30. (Pubitemid 28345371)
49. Kerrouche N, Herholz K, Mielke R, et al. 18FDG PET in vascular dementia: differentiation from Alzheimer's disease using voxel-based multivariate analysis. J Cereb Blood Flow Metab 2006;26: 1213-21. (Pubitemid 44268183)
50. Edison P, Archer HA, Hinz R, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 2007;68:501-8.
51. Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008; 131:665-80. (Pubitemid 351294719)
52. Nelissen N, Van Laere K, Thurfjell L, et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med 2009;50:1251-9.
53. Engler H, Santillo AF, Wang SX, et al. In vivo amyloid imaging with PET in frontotemporal dementia. Eur J Nucl Med Mol Imaging 2008;35: 100-6. (Pubitemid 350234135)
54. Rabinovici GD, Furst AJ, O'Neil JP, et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2007;68: 1205-12. (Pubitemid 46608468)
55. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51: 1546-54.
56. Ishii K, Sakamoto S, Sasaki M, et al. Cerebral glucose metabolism in patients with frontotemporal dementia. J Nucl Med 1998;39:1875-8. (Pubitemid 28518885)
57. Jeong Y, Song YM, Chung PW, et al. Correlation of ventricular asymmetry with metabolic asymmetry in frontotemporal dementia. J Neuroradiol 2005;32: 247-54. (Pubitemid 41441622)
58. Mirzaei S, Knoll P, Koehn H, et al. Assessment of diffuse Lewy body disease by 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET). BMC Nucl Med 2003;3:1.
59. Gilman S, Koeppe RA, Little R, et al. Differentiation of Alzheimer's disease from dementia with Lewy bodies utilizing positron emission tomography with [18F]fluorodeoxyglucose and neuropsychological testing. Exp Neurol 2005;191(Suppl 1): S95-103. (Pubitemid 40081108)
60. Ishii K, Soma T, Kono AK, et al. Comparison of regional brain volume and glucose metabolism between patients with mild dementia with lewy bodies and those with mild Alzheimer's disease. J Nucl Med 2007;48:704-11. (Pubitemid 47604969)
61. Okamura N, Arai H, Higuchi M, et al. [18F]FDG-PET study in dementia with Lewy bodies and Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:447-56. (Pubitemid 32236707)
62. Ransmayr G, Seppi K, Donnemiller E, et al. Striatal dopamine transporter function in dementia with Lewy bodies and Parkinson's disease. Eur J Nucl Med 2001;28:1523-8.
63. McKeith I, O'Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007; 6:305-13. (Pubitemid 46367938)
64. Eckert T, Barnes A, Dhawan V, et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 2005;26:912-21. (Pubitemid 40825033)
65. Juh R, Pae CU, Kim TS, et al. Cerebral glucose metabolism in corticobasal degeneration comparison with progressive supranuclear palsy using statistical mapping analysis. Neurosci Lett 2005;383:22-7. (Pubitemid 40779949)
66. Coulier IM, de Vries JJ, Leenders KL. Is FDG-PET a useful tool in clinical practice for diagnosing corticobasal ganglionic degeneration? Mov Disord 2003;18:1175-8. (Pubitemid 37336943)
67. Garraux G, Salmon E, Peigneux P, et al. Voxel-based distribution of metabolic impairment in corticobasal degeneration. Mov Disord 2000;15: 894-904.
68. Chow TW, Binns MA, Freedman M, et al. Overlap in frontotemporal atrophy between normal aging and patients with frontotemporal dementias. Alzheimer Dis Assoc Disord 2008;22:327-35.
69. Alavi A, Newberg AB, Souder E, et al. Quantitative analysis of PET and MRI data in normal aging and Alzheimer's disease: atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators. J Nucl Med 1993;34: 1681-7. (Pubitemid 23295377)
70. Chawluk J, Alavi A, Dann R, et al. Positron emission tomography in aging and dementia: effect of cerebral atrophy. J Nucl Med 1987;28:431-7. (Pubitemid 17074162)
71. Ibanez V, Pietrini P, Alexander GE, et al. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology 1998;50:1585-93. (Pubitemid 28283222)
72. Chetelat G, Desgranges B, Landeau B, et al. Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease. Brain 2008;131:60-71.
73. He Y, Wang L, Zang Y, et al. Regional coherence changes in the early stages of Alzheimer's disease: a combined structural and resting-state functional MRI study. Neuroimage 2007;35:488-500. (Pubitemid 46400540)
74. Morbelli S, Piccardo A, Villavecchia G, et al. Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxelbased MRI and FDG-PET study. Eur J Nucl Med Mol Imaging 2010;37:36-45.
75. Wienhard K, Schmand M, Casey ME, et al. TheECAT HRRT: performance and first clinical application of the new high resolution research tomograph. IEEE Trans Nucl Sci 2002;49:104-10. (Pubitemid 34658201)
76. Karp JS, Surti S, Daube-Witherspoon ME, et al. Performance of a brain PET camera based on anger-logic gadolinium oxyorthosilicate detectors. J Nucl Med 2003;44:1340-9. (Pubitemid 39655195)
77. Watanabe M, Shimizu K, Omura T, et al. A new high-resolution PET scanner dedicated to brain research. IEEE Trans Nucl Sci 2002;49:634-9. (Pubitemid 35311879)
78. Karp JS, Freifelder R, Geagan MJ, et al. Threedimensional imaging characteristics of the HEAD PENN-PET scanner. J Nucl Med 1997;38:636-43. (Pubitemid 27163663)
79. Yamaya T, Hagiwara N, Obi T, et al. Preliminary resolution performance of the prototype system for a 4-layer DOI-PET scanner: jPET-D4. IEEE Trans Nucl Sci 2006;53:1123-8. (Pubitemid 44109404)
80. K Ziemons, R Achten, E Auffray, et al. The Clear- PET™ neuro scanner: a dedicated LSO/LuYAP phoswich small animal PET scanner. In: Seibert JA, editor. IEEE Nuclear Science Symposium Conference Record, vol. 4 Rome (Italy), October 19-22, 2004. p. 2430-3. (Pubitemid 41148065)
81. Braem A, Chamizo Llatas M, Chesi E, et al. Feasibility of a novel design of high-resolution parallax-free Compton enhanced PET scanner dedicated to brain research. Phys Med Biol 2004;49:2547-62. (Pubitemid 38967944)
82. Braem A, Chesi E, Joram C, et al. Wavelength shifter strips and G-APD arrays for the read-out of the z-coordinate in axial PET modules. Nuclear Instruments and Methods in Physics Research Section A 2008;586:300-8.
83. Worstell W, Adler S, Domigan P, et al. Dynamic brain imaging with low injection dose using the NeuroPET [abstract]. J Nucl Med 2009;50:137P.
84. Vaska P, Woody CL, Schlyer DJ, et al. RatCAP: miniaturized head-mounted PET for conscious rodent brain imaging. IEEE Trans Nucl Sci 2004; 51:2718-22.
85. Yamamoto S, Honda M, Shimizu K, et al. Development of PET-Hat: Wearable PET system for brain research [abstract]. J Nucl Med 2009;50:1532.
86. Morimoto Y, Ueno Y, Tsuchiya K, et al. Performance of a prototype brain PET scanner based on semiconductor detectors. J Nucl Med 2008;49:122P [abstract].
87. Trebossen R, Comtat C, Brulon V, et al. Comparison of two commercial whole body PET systems based on LSO and BGO crystals respectively for brain imaging. Med Phys 2009;36:1399-409.
88. van Velden FHP, Kloet RW, van Berckel BNM, et al. HRRT versus HR1 human brain PET studies: an interscanner test-retest study. J Nucl Med 2009; 50:693-702.
89. Woods RP, Mazziotta JC, Cherry SR. MRI-PET registration with automated algorithm. J Comput Assist Tomogr 1993;17:536-46. (Pubitemid 23206731)
90. Pietrzyk U, Herholz K, Fink G, et al. An interactive technique for three-dimensional image registration: validation for PET, SPECT, MRI and CT brain studies. J Nucl Med 1994;35:2011-8. (Pubitemid 24376621)
91. Slomka P, Baum R. Multimodality image registration with software: state-of-the-art. Eur J Nucl Med Mol Imaging 2009;36:44-55.
92. Hammer BE, Christensen NL, Heil BG. Use of a magnetic field to increase the spatial resolution of positron emission tomography. Med Phys 1994; 21:1917-20.
93. Holdsworth SJ, Bammer R. Magnetic resonance imaging techniques: fMRI, DWI, and PWI. Semin Neurol 2008;28:395-406.
94. Talairach J, Tournoux P. Co-planar atlas of the human brain. New York: Thieme Medical Publishers; 1988.
95. Roland PE, Zilles K. Brain atlases-a new research tool. Trends Neurosci 1994;17:458-67. (Pubitemid 24321944)
96. Friston K, Ashburner J, Heather J, et al. Statistical parametric mapping. Available at: http://www.fil. ion.ucl.ac.uk/spm. Accessed February 10, 2010. The Wellcome Department of Cognitive Neurology, University College London. 1999.
97. Minoshima S, Koeppe RA, Frey KA, et al. Stereotactic PET atlas of the human brain: aid for visual interpretation of functional brain images. J Nucl Med 1994;35:949-54. (Pubitemid 24168122)
98. Slomka PJ, Radau P, Hurwitz GA, et al. Automated three-dimensional quantification of myocardial perfusion and brain SPECT. Comput Med Imaging Graph 2001;25:153-64. (Pubitemid 32011243)
99. Herholz K, Salmon E, Perani D, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 2002;17:302-16.
100. Sanchez-Crespo A, Andreo P, Larsson SA. Positron flight in human tissues and its influence on PET image spatial resolution. Eur J Nucl Med Mol Imaging 2004;31:44-51. (Pubitemid 38133540)
101. Rousset O, Rahmim A, Alavi A, et al. Partial volume correction strategies in PET. PET Clin 2007;2:235-49.
102. Zaidi H, Montandon M-L. Scatter compensation techniques in PET. PET Clin 2007;2:219-34.
103. Zaidi H, Montandon M-L, Meikle S. Strategies for attenuation compensation in neurological PET studies. Neuroimage 2007;34:518-41. (Pubitemid 44830173)
104. Rahmim A, Rousset O, Zaidi H. Strategies for motion tracking and correction in PET. PET Clin 2007;2:251-66.
105. Reader AJ, Zaidi H. Advances in PET image reconstruction. PET Clin 2007;2:173-90.
106. Meltzer CC, Cantwell MN, Greer PJ, et al. Does cerebral blood flow decline in healthy aging? A PET study with partial-volume correction. J Nucl Med 2000;41:1842-8.
107. Muller-Gartner HW, Links JM, Prince JL, et al. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab 1992;12:571-83.
108. Matsuda H, Ohnishi T, Asada T, et al. Correction for partial-volume effects on brain perfusion SPECT in healthy men. J Nucl Med 2003;44:1243-52. (Pubitemid 39655184)
109. Meltzer CC, Kinahan PE, Greer PJ, et al. Comparative evaluation of MR-based partialvolume correction schemes for PET. J Nucl Med 1999;40:2053-65. (Pubitemid 30022022)
110. Zaidi H, Ruest T, Schoenahl F, et al. Comparative evaluation of statistical brain MR image segmentation algorithms and their impact on partial volume effect correction in PET. Neuroimage 2006;32: 1591-607. (Pubitemid 44332287)
111. Tohka J, Reilhac A. Deconvolution-based partial volume correction in Raclopride-PET and Monte Carlo comparison to MR-based method. Neuroimage 2008;39:1570-84.
112. Boussion N, Hatt M, Lamare F, et al. A multiresolution image based approach for correction of partial volume effects in emission tomography. Phys Med Biol 2006;51:1857-76.
113. Shidahara M, Tsoumpas C, Hammers A, et al. Functional and structural synergy for resolution recovery and partial volume correction in brain PET. Neuroimage 2009;44:340-8.
114. Baete K, Nuyts J, Laere KV, et al. Evaluation of anatomy based reconstruction for partial volume correction in brain FDG-PET. Neuroimage 2004; 23:305-17. (Pubitemid 39119461)
115. M Montandon, F Assal, O Ratib, et al. MRIguided voxel-based partial volume effect correction in brain PET: assessment of the impact of 3 MR image segmentation algorithms. 15th Annual Meeting, Organization for Human Brain Mapping (HBM). San Francisco, June 18-23, 2009;47:365.
116. Kohn MI, Tanna NK, Herman GT, et al. Analysis of brain and cerebrospinal fluid volumes with MR imaging. Part I. Methods, reliability, and validation. Radiology 1991;178:115-22.
117. Bural GG, Zhuge Y, Torigian DA, et al. Partial volume correction and segmentation allows accurate measurement of SUV for the grey matter in the brain [abstract]. J Nucl Med 2006;47:9P.
118. Basu S, Zaidi H, Houseni M, et al. Novel quantitative techniques for assessing regional and global function and structure based on modern imaging modalities: implications for normal variation, aging and diseased states. Semin Nucl Med 2007;37: 223-39. (Pubitemid 46533824)
119. Zaidi H, Montandon M, Alavi A. The clinical role of fusion imaging using PET, CT and MRI. Magn Reson Imaging Clin N Am 2010;18:133-49.